G protein-coupled receptor fusion proteins in drug discovery

Current Pharmaceutical Design

Volumn 10, Issue 17, 2004, Pages 1989-2001

  Milligan, G ^a   Feng, G J ^a   Ward, R J ^a   Sartania, N ^a   Ramsay, D ^a   McLean, A J ^a   Carillo, J J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Assay development; Enzyme complementation; G protein coupled receptor; Green fluorescent protein

Indexed keywords

CYANINE DYE; DRUG; G PROTEIN COUPLED RECEPTOR; GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; PARTIAL AGONIST; PEPTIDE DERIVATIVE; POLYPEPTIDE; REAGENT; RECEPTOR BLOCKING AGENT;

ALPHA CHAIN; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG TARGETING; GENE CONSTRUCT; LIGAND BINDING; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STABILITY; REPORTER GENE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DESIGN; GREEN FLUORESCENT PROTEINS; HUMANS; LIGANDS; PROTEIN SUBUNITS; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT FUSION PROTEINS;

EID: 3042615072     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384295     Document Type: Review

References (140)

1. Chalmers DT, Behan DP. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov 2002; 1: 599-608.
2. Lee DK, George SR, O'Dowd BF. Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets Expert Opin Ther Targets 2002; 6: 185-202.
3. Im DS. Orphan G protein-coupled receptors and beyond. Jpn J Pharmacol 2002; 90:101-104.
4. Milligan G. Strategies to identify ligands for orphan G protein-coupled receptors. Biochem Soc Trans 2002; 30: 4, 789-793
5. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002; 7: 235-246.
6. Moore K, Rees S. Cell-based versus isolated target screening: how lucky do you feel? J Biomol Screen 2001; 6:69-74.
7. Ghosh RN, Chen YT, DeBiasio R, DeBiasio RL, Conway BR, Minor LK, et al. Cell based, high content screen for receptor internalisation recycling and intracellular trafficking. Biotechniques 2000; 29: 170-175.
8. Seifert R, Wenzel-Seifert K, Kobilka BK. GPCR-Gα fusion proteins: molecular analysis of receptor-G-protein coupling. Trends Pharmacol Sci 1999; 20: 383-389.
9. Milligan G. Insights into ligand pharmacology using receptor -G-protein fusion proteins. Trends Pharmacol Sci 2000; 21: 24-28.
10. Wurch T, Pauwels PJJ. Analytical pharmacology of G protein-coupled receptors by stoichiometric expression of the receptor and G(α) protein subunits. J Pharmacol Toxicol Methods 2001; 45: 3-16.
11. Milligan G. Construction and analysis of function of G protein-coupled receptor-G protein fusion proteins. Methods Enzymol 2002; 343: 260-73.
12. Adie EJ, Kalinka S, Smith L, Francis MJ, Marenghi A, Cooper ME, et al. A pH-sensitive fluor, CypHer(TM) 5, used to monitor agonist-induced G protein-coupled receptor internalisation in live cells. Biotechniques 2002; 33: 1152-1157.
13. Eglen RM. Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Develop Tech 2003; 1: 97-104.
14. Wehrman T, Kleaveland B, Her JH, Balint RF, Blau HM. Protein-protein interactions monitored in mammalian cells via complementation of β-lactamase enzyme fragments. Proc Natl Acad Sci USA 2002; 99: 3469-3474.
15. Hu CD, Chinenov Y, Kerppola TK. Molecular architecture of SMC proteins and the yeast cohesin complex. Mol Cell 2002; 9: 789-798.
16. Tsien RY. The green fluorescent protein. Annu Rev Biochem 1998; 67: 509-544.
17. Zimmer M. Green fluorescent protein (GFP): applications, structure, and related photophysical behaviour. Chem Rev 2002; 102: 759-782.
18. Matz MV, Lukyanov KA, Lukyanov SA. Family of the green fluorescent protein: journey to the end of the rainbow. Bioessays 2002; 24(10): 953-959.
19. Labas YA, Gurskaya NG, Yanushevich YG, Fradkov AF, Lukyanov KA, Lukyanov SA, et al. Diversity and evolution of the green fluorescent protein family. Proc Natl Acad Sci USA 2002; 99: 4256-4261.
20. Baird GS, Zacharias DA, Tsien RY. Biochemistry, mutagenesis, and oligomerization of DsRed, a red fluorescent protein from coral. Proc Natl Acad Sci USA 2000; 97: 11984-11989.
21. Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci USA 2002; 99: 7877-7882.
22. Milligan G. Exploring the dynamics of regulation of G protein-coupled receptors using green fluorescent protein. Br J Pharmacol 1999; 128: 501-510.
23. Kallal L, Benovic JL. Using green fluorescent proteins to study G-protein-coupled receptor localization and trafficking. Trends Pharmacol Sci 2000; 21: 175-180.
24. Tsao P, Cao T, von Zastrow M. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 2001; 22: 91-96.
25. Tsao PI, von Zastrow M. Diversity and specificity in the regulated endocytic membrane trafficking of G-protein-coupled receptors. Pharmacol Ther 2001; 89:139-147.
26. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling. Pharmacol Rev 2001; 53: 1-24.
27. Claing A, Laporte SA, Caron MG, Lefkowitz RJ. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and β-arrestin proteins. Prog Neurobiol 2002; 66: 61-79.
28. Ghosh RN, Chen YT, De Biasio R, De Biasio RL, Conway BR, Minor LK, et al. Cell-based, high-content screen for receptor internalization, recycling and intracellular trafficking. Biotechniques 2000; 29: 170-175.
29. Conway BR, Minor LK, Xu JZ, D'Andrea MR, Ghosh RN, Demarest KT. Quantitative analysis of agonist-dependent parathyroid hormone receptor trafficking in whole cells using a functional green fluorescent protein conjugate. J Cell Physiol 2001; 189: 341-355.
30. McLean AJ, Milligan G. Ligand regulation of green fluorescent protein-tagged forms of the human beta(1)- and beta(2)-adrenoceptors; comparisons with the unmodified receptors. Br J Pharmacol 2000; 130: 1825-1832.
31. 1-adrenergic receptor association with the synaptic scaffolding protein membrane-associated guanylate kinase inverted-2 (MAGI-2). J Biol Chem 2001; 276: 41310-41317.
32. 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc Natl Acad Sci USA 2003; 100: 342-346.
33. + exchanger regulatory factor family of PDZ proteins. Proc Natl Acad Sci USA 1998; 95: 8496-8501.
34. 2-adrenergic receptor. Nature 1999; 401: 286-290.
35. Gage RM, Kim KA, Cao TT, von Zastrow M. A transplantable sorting signal that is sufficient to mediate rapid recycling of G protein-coupled receptors. J Biol Chem 2001; 276: 44712-44720.
36. Milasta S, Evans N, Groarke DA, Wilson S, Milligan G. High affinity interactions between the orexin-1 receptor and β -arrestin-2 are determined by a single C-terminal cluster of hydroxy amino acids 2004; (submitted for publication).
37. 1-adrenergic receptor for β-arrestins explains the resistance to agonist-induced internalization. Life Sci 68: 2251-2257.
38. 2-Adrenergic and angiotensin II type 1A receptors. Mol Endocrinol 2000; 14: 2040-2053.
39. Evans NA, Groarke DA, Warrack J, Greenwood CJ, Dodgson K, Milligan G, et al. Visualizing differences in ligand-induced β-arrestin-GFP interactions and trafficking between three recently characterized G protein-coupled receptors. J Neurochem. 2001; 77: 476-485.
40. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, β-arrestin1 and β -arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000; 275: 17201-17210.
41. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. Desensitization, internalization, and signaling functions of β -arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 2003; 100: 1740-1744.
42. Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ. β-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 2001; 98: 1601-1606.
43. 1-adrenoceptor ligand-binding sites. J Pharmacol Exp Ther 2000; 294: 433-434.
44. Sugawara T, Hirasawa A, Hashimoto K, Tsujimoto G. Differences in the subcellular localization of α1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci 2000; 70: 2113- 2124.
45. Boivin B, Chevalier D, Villeneuve LR, Rousseau E, Allen BG. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003; 278: 29153-29163.
46. 4 in the nuclear envelope. J Biol Chem 1999; 274: 15719-15724.
47. Fraile-Ramos A, Kledal TN, Pelchen-Matthews A, Bowers K, Schwartz TW. The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling. Mol Biol Cell 2001; 12: 1737-1749.
48. Fraile-Ramos A, Pelchen-Matthews A, Kledal TN, Browne H, Schwartz TW, Marsh M. Localization of HCMV UL33 and US27 in endocytic compartments and viral membranes. Traffic 2002; 3: 218-232.
49. Whistler JL, Gerber BO, Meng EC, Baranski TJ, von Zastrow M, Bourne HR. Constitutive activation and endocytosis of the complement factor 5a receptor: Evidence for multiple activated conformations of a G protein-coupled receptor. Traffic 2002; 3: 866-877.
50. Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP, Bouvier M. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J 2002; 21: 1628-1637.
51. Petaja-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, Bouvier M. Newly synthesized human δ opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J Biol Chem 2001; 276: 4416-4423.
52. Milligan G, Stevens PA, Ramsay D, McLean AJ. Ligand rescue of constitutively active mutant receptors. Neurosignals 2002; 11: 29-33.
53. 2-adrenoceptor in transfected neuroblastoma x glioma hybrid cells. Mol Pharmacol 1996; 50: 1479-1486.
54. 2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 1997; 399: 108-112.
55. 1B-adrenoceptor by ligands that act as inverse agonists. Biochem J 1997; 325: 733-739.
56. Zhu J, Taniguchi T, Takauji R, Suzuki F, Tanaka T, Muramatsu I. Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor. Br J Pharmacol 2000; 131: 546-552.
57. 2-adrenoceptor-green fluorescent protein fusion proteins. Mol Pharmacol 1999; 56: 1182-1191.
58. 1b-adrenoceptor. Mol Pharmacol 2000; 58: 438-448.
59. Hill SJ, Baker JG, Rees S. Reporter-gene systems for the study of G-protein-coupled receptors. Curr Opin Pharmacol 2001; 1: 526-532.
60. Dinger MC, Beck-Sickinger AG. The first reporter gene assay on living cells: green fluorescent protein as reporter gene for the investigation of Gi-protein coupled receptors. Mol Biotechnol 2002; 21: 9-18.
61. Stables J, Scott S, Brown S, Roelant C, Burns D, Lee MG, et al. Development of a dual glow-signal firefly and Renilla luciferase assay reagent for the analysis of G-protein coupled receptor signalling. J Recept. Signal Transduct Res 1999; 19: 395-410.
62. Ramsay D, Bevan N, Rees S, Milligan G. Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor. Br J Pharmacol 2001; 133: 315-323.
63. 3 chimeric G protein-coupled receptor. Mol Pharmacol 2003; 64: 1474-1484.
64. Eidne KA, Kroeger KM, Hanyaloglu AC. Applications of novel resonance energy transfer techniquee to study dynamic hormone receptor interactions in living cells. Trends Endocrinol Metabol 2002; 13: 415-421.
65. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-820.
66. Angers S, Salahpour A, Bouvier M. Dimerization: An emerging concept of G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002; 42: 409-435.
67. Mellado M, Vila-Coro AJ, Martinez C, Rodriguez-Frade JM. Receptor dimerization: a key step in chemokine signaling. Cell Mol Biol 2001; 47: 575-582.
68. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, Eidne KA. Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using biolominescence resonance energy transfer. J Biol Chem 2001; 276: 12736-12743.
69. Cheng ZJ, Miller LJ. Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001; 276: 48040-480407.
70. Latif R, Graves P, Davies TF. Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor. J Biol Chem 2002; 277: 45059-45067.
71. McVey M, Ramsay D, Kellett E, Rees S, Wilson S, Pope AJ, et al. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. J Biol Chem 2001; 276: 14092-14099.
72. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002; 277: 21522-21528.
73. Babcock GJ, Farzan M, Sodroski J. Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem 2003; 278: 3378-3385.
74. Barak LS, Ferguson SS, Zhang J, Caron MG. A β-Arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 1997; 272: 27497-27500.
75. 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000; 97: 3684-3689.
76. Hanyaloglu AC, Seeber RM, Kohout TA, Lefkowitz RJ, Eidne KA. Homo- and hetero-oligomerization of thyrotropin-releasing hormone (TRH) receptor subtypes. J Biol Chem 2002; 277: 50422-50430.
77. Oakley RH, Hudson CC, Cruikshank RD, Meyers DM, Payne Jr RE, Rhem SM, et al. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay Drug Devel Tech 2002; 1: 21-30.
78. Bertrand L, Parent S, Caron M, Legault M, Joly E, Angers S, et al. The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). J Recept Signal Transduct Res 2002; 22: 533-541.
79. Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR. The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor all agonist-induced β-arrestin 2 interaction. J. Pharmacol. Exp. Ther. 2003; 306: 147-156.
80. s fusion protein. Proc Natl Acad Sci USA 1994; 91: 8827-8831.
81. Seifert R, Wenzel-Seifert K, Kobilka BK. GPCR-Gα fusion proteins: molecular analysis of receptor-G-protein coupling. Trends Pharmacol Sci 2000; 20: 383-389.
82. s. J Biol Chem 1999; 274: 31014-31019.
83. 2-adrenergic receptor to engineer a receptor-effector complex for gene therapy. J Biol Chem 2001; 276: 31596-31601.
84. Scearce-Levie K, Coward P, Redfern CH, Conklin BR. Tools for dissecting signaling pathways in vivo: receptors activated solely by synthetic ligands. Methods Enzymol 2002; 343:232-248.
85. Scearce-Levie K, Coward P, Redfern CH, Conklin BR. Engineering receptors activated solely by synthetic ligands (RASSLs). Trends Pharmacol Sci 2001; 22: 414-420.
86. i1α fusion protein. Biochem J 1997; 325: 17-21.
87. Milligan G. Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 2000; 21: 24-28.
88. Milligan G. Construction and analysis of function of G protein-coupled receptor-G protein fusion proteins. Methods Enzymol 2002; 343: 260-273.
89. Milligan G. The use of receptor G-protein fusion proteins for the study of ligand activity. Receptors Channels 2002; 8: 309-317.
90. Fong CW, Milligan G. Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins. Biochem J 1999; 342: 457-463.
91. 1-Adrenoceptor. Mol Pharmacol 2002; 62:747-755.
92. s. J Pharmacol Exp Ther 2001; 299: 1013-1020.
93. s splice variants. Biochem Pharmacol 2002; 64: 9-20.
94. Ugur O, Onaran HO, Jones TL. Partial rescue of functional interactions of a nonpalmitoylated mutant of the G-protein G alpha s by fusion to the beta-adrenergic receptor. Biochemistry 2003; 42: 2607-2615.
95. s. J Biol Chem 2000; 275: 21631-21638.
96. Holst B, Hastrup H, Raffetseder U, Martini L, Schwartz TW. Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J Biol Chem 2001; 276: 19793-19799.
97. i1α by expressing the proteins from chimeric open reading frames. J Biol Chem 1997; 272: 24673-24678.
98. Moon H-E, Bahia DS, Cavalli A, Hoffman M, Milligan G. Control of the efficiency of agonist-induced information transfer and stability of the ternary complex containing the delta opioid receptor and the alpha subunit of G(i1) by mutation of a receptor/G protein contact interface. Neuropharmacology 2001; 41: 321-330.
99. 1-adenosine receptor and G protein α-subunits. J Biol Chem 1999; 274: 30571-30579.
100. 1A receptor by mutation of a receptor contact site on the interacting G protein α subunit. Br J Pharmacol 2002; 137: 345-352.
101. o1α. J Neurochem 2001; 76: 1805-1813.
102. i1 α. Mol Pharmacol 1999; 56: 684-692.
103. 1l α is not required for interaction with β/γ complex. J Biol Chem 2001; 276: 35883-35890.
104. 1l. J Pharmacol Exp Ther 2002; 302: 1080-1088.
105. 1l , requires both β/γ interactions and all aromatic group four amino acids from the C terminus of the G protein. J Biol Chem 2002; 277: 25707-25714.
106. q-proteins. Mol Pharmacol 2000; 58: 954-966.
107. Pauwels PJ, Colpaert FC. Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites. Br J Pharmacol 2000; 130: 1505-1512.
108. Martin RS, Reynen PH, Calixto JJ, Reyes CL, Chang TK, Dietrich PS, et al. Pharmacological comparison of a recombinant CB1 cannabinoid receptor with its G(alpha 16) fusion product. J Biomol Screen 2002; 7: 281-289.
109. 35S]GTPγS binding assays. Trends Pharmacol Sci 2003; 24: 87-90.
110. i1α. Mol Pharmacol 1999; 55: 195-201.
111. Welsby PJ, Kellett E, Wilkinson G, Milligan G. Enhanced detection of receptor constitutive activity in the presence of regulators of G protein signaling: applications to the detection and analysis of inverse agonists and low-efficacy partial agonists. Mol Pharmacol 2002; 61: 1211-1221.
112. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: a G protein coupled receptor. Science 2000; 289: 739-745.
113. Yeagle PL, Choi G, Albert AD. Studies on the structure of the G-protein-coupled receptor rhodopsin including the putative G-protein binding site in unactivated and activated forms. Biochemistry 2001; 40: 11932-11937.
114. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001; 60: 1-19.
115. Lu ZL, Saldanha JW, Hulme EC. Seven-transmembrane receptors: Crystals clarify. Trends Pharmacol Sci 2002; 23: 140-146.
116. 2-adrenergic receptor to Gαs in mammalian cells: Identification of a specific signal transduction species not characteristic of constitutive activation or precoupling. Biochemistry 2000; 39: 2815-2821.
117. v2.2 calcium channels: probed by the use of receptor-Gα tandems. Mol Pharmacol 2003; 63: 832-843.
118. Milligan G. Altering the relative stoichiometry of receptors, G-proteins and effectors: effects on agonist function. In: The pharmacology of functional, biochemical, and recombinant receptor svstems. Handb Exp Pharm 2000; 148: (eds Kenakin T. and Angus J.A) pp 363-389.
119. 1-adrenoceptor Br. J Pharmacol 2003; 138: 279-282.
120. Medici R, Bianchi E, Di Segni G, Tocchini-Valentini GP. Efficient signal transduction by a chimeric yeast-mammalian G protein α subunit Gpa1-Gsα covalently fused to the yeast receptor Ste2. EMBO J 1997; 16: 7241-7249.
121. Conklin BR, Herzmark P, Ishida S, Voyno-Yasenetskava TA, Sun Y, Farfel Z, et al. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. Mol Pharmacol 1996; 50: 885-890.
122. Feng GJ, Cavalli A, Milligan G. Engineering a V(2) vasopressin receptor agonist- and regulator of G-protein-signaling-sensitive G protein. Anal Biochem 2002; 300: 212-220.
123. Fukushima N, Ishii I, Contos JJA, Weiner JA, Chun J. Lysophospholipid Receptors. Annu Rev Pharmacol Toxicol 2001; 41: 507-534.
124. ilα coexpression and fusion protein studies. Mol Pharmacol 2000; 58: 407-412.
125. i/o. J Biol Chem 2002; 277: 31459-31465.
126. 14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003; 24: 52-55.
127. Milligan G, Marshall F, Rees S. G16 as a universal G protein adapter: Implications for agonist screening strategies. Trends Pharmacol Sci 1996; 17: 235-237.
128. Bahia DS, Sartania N, Ward RJ, Cavalli A, Jones TLZ, Drucy KM, et al. Concerted stimulation and deactivation of pertussis toxin-sensitive G proteins by chimeric G protein-coupled receptor-regulator of G protein signaling 4 fusion proteins: analysis of the contribution of palmitoylated cysteine residues to the GAP activity of RGS4. J. Neurochem 2003; 85: 1289-1298.
129. 1 receptor and NTPDase1 exhibits functional activities of the native receptor and ectoenzyme and reduced signaling responses to endogenously released nucleotides. Mol Pharmacol 2002; 62: 521-528.
130. Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M et al. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene 2002: 21: 1658-1667.
131. Galarneau A, Primeau M, Trudeau LE, Michnick SW. β-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein interactions. Nature Biotechnol 2002; 20: 619-622.
132. Blakely BT, Rossi FM, Tillotson B, Palmer M, Estelles A, Blau HM. Epidermal growth factor receptor dimerization monitored in live cells. Nature Biotechnol 2000; 18: 218-222.
133. Graham DL, Bevan N, Lowe PN, Palmer M, Rees S. Application of β-galactosidase enzyme complementation technology as a high throughput screening format for antagonists of the epidermal growth factor receptor. J Biomol Screen 2001; 6: 401-411.
134. Boute N, Pernet K, Issad T. Monitoriag the activation state of the insulin receptor using bioluminescence resonance energy transfer. Mol Pharmacol 2001; 60: 640-645.
135. Adie EJ, Kalinka S, Smith L, Francis MJ, Marenghi A, Cooper ME, et al. A pH-sensitive fluor, CypHer 5, used to monitor agonist-induced G protein-coupled receptor internalization in live cells. Biotechniques 2002; 33: 1152-1154.
136. Adie E, Francis MJ, Davies J, Smith L, Marenghi A, Hather C, et al. CypHer 5- a generic approach for measuring the activation and trafficking of G-protein-coupled receptors in live cells. Assays Drug Develop Technol 2003; 1: 251-259.
137. Milligan G. High-content assays for ligand regulation of G-protein-coupled receptors. Drug Discovery Today 2003; 8: 579-585.
138. de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Beta-glucuronidase-mediated drug release. Curr Pharm Design 2002; 8(15): 1391-403.
139. Horvath TL, Castaneda T, Tang-Christensen M, Pagotto U, Tschop MH. Ghrelin as a potential anti-obesity target. Curr Pharm Design 2003; 9(17): 1383-95.
140. Jiang S, Zhao Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Design 2002; 8(8): 563-80.